Mycobacterium intracellulare M.i.198—A Promising Strain for Studying Pathogenesis of Nontuberculous Mycobacterial Pulmonary Disease (NTM‐PD) Authors: Yoshitaka Tateishi, Ryoji Maekura, Yukiko Nishiuchi, Sohkichi Matsumoto Published: 2026 ABSTRACT ABSTRACTIn this review, we introduce a promising strain for studying pathogenesis of nontuberculous mycobacterial pulmonary disease (NTM‐PD), Mycobacterium intracellulare M.i.198. M.i.198 was isolated from a patient with progressive Mycobacterium avium‐intracellulare complex pulmonary disease (MAC‐PD) in whom surgical operation was required to suppress disease progression. M.i.198 shows progressive illness in infected mice in terms of bacterial load, inflammation, and by high‐dose inoculation, mortality as well. Although M.i.198 is resistant to clarithromycin, the pathogenicity of M.i.198 in mice indicates the high potency for use to evaluate drug efficacies in vivo. Furthermore, M.i.198 can be genetically manipulated, which is quite different from other MAC strains, especially those of M. avium subsp. hominissuis. We herein report the bacteriological findings, experimental virulence and functional genomic features of M.i.198 with a small review of MAC strains used for animal models of MAC‐PD.Keywords: animal model, gene manipulation, Mycobacterium intracellulare, nontuberculous mycobacteria, pathogenesis, virulence Abbreviations Amikacin Clarithromycin Coding sequence Colony forming units Clustered regularly interspaced short palindromic repeat‐deactivated CRISPR‐associated protein 9 Glycopeptidolipids Hypoxia inducible factor‐1α Human immunodeficiency virus/acquired immunodeficiency syndrome Mycobacterium avium‐intracellulare complex pulmonary disease Matrix metalloproteases M. praintracellulare‐M. indicus pranii Mycobacterium tuberculosis Nontuberculous mycobacterial pulmonary disease Streptomycin tuberculosis Typical M. intracellulare Transposon sequencing Introduction NTM‐PD is an emerging infectious disease worldwide including Japan, Asia, U.S. and Europe. NTM research in aspects of epidemiology and clinical medicine has been accumulated in Japan [1, 2, 3, 4, 5]. Although the incidence rate of NTM‐PD was less than 1 case per 100,000 person‐years in 1980, it has been increasing from 5.7 to 14.7 cases per 100,000 person‐years between 2007 and 2014 [1]. In Japan, 1,158 people were dead caused by NTM‐PD, which was 1.45‐fold higher than the number of deaths caused by tuberculosis (TB), according to the demographic statistics in Japan reported in 2022. The clinical course of NTM‐PD varies widely. Approximately 20% of patients showing bronchiectatic disease phenotype, which is common in middle‐aged women, do not exhibit progressive illness without chemotherapy [6]. On the other hand, approximately 39.8% of fibrocavitary NTM‐PD disease patients exhibit progressive illness regardless of chemotherapy [7]. The treatment of NTM‐PD is more difficult than drug‐sensitive TB, partly because medication should be recommended for additional 12 months after sputum culture become negative [8]. Clarithromycin (CAM) is a key drug for NTM‐PD, and the resistance to CAM is associated with poor prognosis [8]. Moreover, the treatment failure sometimes occurs by the side effect of drugs and medication compliance. In some cases, mycobacteria inside patients' lung acquire resistance to the drugs. It is unknown how and why NTM‐PD patients undergo chronic course of disease and results in death in the worst cases. Therefore, bacteriological study including establishment of animal models of NTM‐PD is necessary to clarify pathogenesis and to evaluate drug efficacies in vivo. There are approximately 200 species of NTM, and the major causative agent of NTM‐PD is Mycobacterium avium‐intracellulare complex (MAC) in Japan [1]. The distribution of causative agents of NTM‐PD shows regional characteristics. For example, M. avium distributes predominantly in eastern Japan, and M. intracellulare distributes predominantly in western Japan [1]. M. abscessus, an emerging etiological agent of NTM‐PD, distributes in far western areas including Kyusyu and Okinawa [1]. M. intracellulare is the most prevalent agent of NTM‐PD in China, and M. intracellulare and M. fortuitum are predominant in India [9]. M. fortuitum and M. abscessus distributes predominantly in Java‐Indonesia [10]. M. avium as well as M. intracellulare and related species such as M. intracellulare subsp. chimaera prevails in Australia, U.S. and Europe [11, 12]. NTM is ubiquitous in nature such as water, soil as well as residential bathrooms [13, 14]. The typical example is M. marinum and M. ulcerans, which cause waterborne skin diseases. As for NTM‐PD, the route of infection is considered to be airways. So far, environmental exposure of NTM as well as disorder of lung structure are proposed as main drivers of pulmonary disease. Showerheads and bathtub inlets are evidenced to be the reservoir of MAC by the coincidence of genotypes of MAC between sputum and environmental samples [14]. Fibrocavitary disease, which is found less frequently nowadays than in early 2000s in Japan, occurs based on the existing damage of lung structures such as sequela of pulmonary tuberculosis (TB), chronic obstructive pulmonary disease (COPD) and pneumoconiosis [8]. On the other hand, nodular bronchiectasis disease, which mainly consists of increasing number of NTM‐PD patients, is considered to occur without the existing damage of lung structures or without obvious disorders of host immune response [8]. Excluding disseminated MAC disease caused by disorders of cellular immune response such as human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) [15] or disorders of interferon‐γ (IFN‐γ) immune response, such as autoantibodies against IFN‐γ and IFN‐γ receptor mutation [16, 17], most patients do not have an obvious background of immunological disorders. From the viewpoint of epidemiologically high incidence as well as scientifically unproven situation, NTM‐PD is the major issue caused by MAC. In this article, we perform a small review of representative MAC strains that have been used for models of MAC‐PD. And we introduce the hypervirulent M. intracellulare strain designated as M.i.198, which was isolated from a patient exhibiting rapid disease progression within 3 years and demonstrated to be hypervirulent in C57BL/6 mice [18, 19, 20, 21, 22]. M.i.198 can be used for a wide variety of experiments, such as mouse infection, gene recombination and functional assay (Figure 1). We consider this review provides useful information for establishing experiment systems to elucidate pathogenesis of MAC‐PD and to develop novel therapies. Application of Mycobacterium intracellulare M.i.198 in basic studies of NTM pulmonary disease. The Representative MAC Strains Previously Used for Animal Models of MAC‐PD Since attention had been paid on AIDS‐related MAC disease from 1980s to 1990s, there were no reports on the virulence of clinical MAC strains after infection through the airway in animal models until the beginning of 2000s. As experimental models, M. avium subsp. hominissuis strains 101 and 104 (MAC101 and MAC104) have been used long period (Table 1) [23, 24, 25, 26, 27]. However, it is questionable whether the strains isolated from blood in patients with AIDS‐related systemic MAC disease as well as the strains genomically distant from recently emerging MAC‐PD strains [33] cause similar pathogenesis of MAC‐PD without obvious predisposing immunological disorders. From 2010s, some researchers isolated clinical strains from MAC‐PD patients and infected mice with these strains through airways [28, 29, 30, 31]. Since CAM is a key drug for NTM‐PD [8], CAM has been used as a control drug for experimental infection models employing these M. avium strains. In these aspects, the conventional M. avium strains are useful for evaluation of drug efficacies by measuring bacterial burden such as colony forming units (CFUs). However, the mortality of infected mice with these strains has not been reported to be high unless mice are immunodeficient such as deficiency of a transcription factor nuclear factor erythroid 2‐related factor (Nrf2), which regulates the expression of antioxidant proteins, or deficiency of a component of the NADPH oxidase in neutrophils Gp91phox, which makes it difficult to evaluate the effect of chemotherapy in vivo by mortality rate. Moreover, the possibility of gene manipulation of M. avium strains including strains 101, 104 and above‐mentioned clinical strains isolated from MAC‐PD patients has not been proved, which makes it difficult to proceed further genetic and functional analysis in mycobacteria. In fact, gene manipulation of M. avium, such as transposon mutagenesis and gene deletion is markedly difficult based on the lack of successive reports on manipulation of various genes in M. avium, especially M. avium subsp. hominissuis including MAC104 and other clinical strains [32, 34]. Under such circumstances, we have focused on M. intracellulare as a promising NTM species for bacteriological research including animal models and gene manipulation analysis. Table 1The representative MAC strains used for animal models of MAC‐PD.MAC strain M. avium subsp. hominissuis MAC101 (ATCC700898) M. avium subsp. hominissuis MAC104 M. avium subsp. hominissuis (TH48) M. avium FN M. intracellulare M.i.198SourceAIDS, bloodAIDS, bloodMAC‐PD, sputumMAC‐PD possibly, sputum possiblyMAC‐PD, sputumRoute of infectionAE [23, 24], I.B [25].AE [24], I.N [26]., I.P [27].I.N [28, 29, 30].I.T [31].I.T [18, 19].Host speciesMouse (C57BL/6 [23], BALB/c [23, 24], Swiss [23], nude [23], beige [23]), Rhesus macaque [25]Mouse (C57BL/6 [26, 27], BALB/c [24])Mouse (BALB/c) [28, 29, 30]Mouse (C57BL/6) [31]Mouse (C57BL/6) [18, 19]Mortality of infected animalsNo reportNo reportAbout 50% mice are dead at 6 weeks of infection in Nrf2‐deficient mice [28].About 40% mice are dead at 6 weeks of infection in gp91‐phox‐deficient mice [31].About 50% and 70% mice are dead after 6 and 16 weeks of infection with 2 × 107 CFU bacteria in wild‐type mice [18].Evaluation of chemotherapeutic efficaciesCAM can be used as a control drug [24]CAM can be used as a control drug [24]No reportNo reportAMK can be used as the control drug instead of CAM [18].Genetic studies including gene manipulationNo reportOne report showing MAC 104 expressing firefly luciferase and MAC104 expressing green fluorescent protein [27]. One report showing deletion of methyltransferase D gene of GPL by allelic exchange [32].No reportNo report Transposon mutagenesis and TnSeq [20]. Transformation of a vector expressing firefly luciferase, and CRISPR‐i vectors [20]. Abbreviations: AE, aerosol; CRISPR‐i, clustered regularly interspaced short palindromic repeats‐interference; GPL, glycopeptidolipid; I.B, intrabronchial; I.N, intranasal; I.P, intraperitoneal; I.T, intratracheal; TnSeq, transposon sequencing. The representative MAC strains used for animal models of MAC‐PD. Transposon mutagenesis and TnSeq [20]. Transformation of a vector expressing firefly luciferase, and CRISPR‐i vectors [20]. Abbreviations: AE, aerosol; CRISPR‐i, clustered regularly interspaced short palindromic repeats‐interference; GPL, glycopeptidolipid; I.B, intrabronchial; I.N, intranasal; I.P, intraperitoneal; I.T, intratracheal; TnSeq, transposon sequencing. The Source of M. intracellulare Strain M.i.198 We isolated M. intracellulare strain named M.i.198 from the MAC‐PD patient who showed progressive illness within 3 years despite the multi‐drug chemotherapy, and surgical operation of pneumonectomy was needed to control the progression of illness [18]. M.i.198 was isolated from this patient immediately before surgical operation in 2003. Possibly due to the muti‐drug chemotherapy, M.i.198 is resistant to CAM (Table 1), which may make it difficult to use for evaluation of drug efficacies, especially of macrolides as describe later. The detail of the clinical course is shown in Supplemental Information. Colony Morphology of M.i.198 The dominant colony morphology of M.i.198 is smooth opaque (SmO) (Figure 2). The colony morphology of M.i.198 is quite different from the M. intracellulare type strain ATCC13950, which exhibits dome‐shaped SmO colonies. From an empirical point of view, both smooth transparent (SmT) and SmO colonies can be simultaneously isolated from clinical samples, and single isolation of such mixed colonies is difficult. Furthermore, spontaneous changes in colony morphology can be observed in some cases by subculture in NTM. The biological meaning of colony morphology in NTM has not been fully elucidated in contrast to the cases in general bacteria. Nonetheless, the colony morphology of M.i.198 can be often seen in clinical NTM isolates. Colony morphology of M. intracellulare M.i.198 (a) and ATCC13950 (b). The colonies were grown on Middlebrook 7H10/OADC agar. The photographs were originally taken for this Mini‐Review. The M.i.198 isolate is a new serotype (similar to serotype 12) [18]. The detail of a course of serotypes is shown in Supplemental Information. M.i.198 ­ a Promising Strain for Studying In Vivo Pathogenesis and Drug Efficacy To determine the optimal strain for mouse model of MAC‐PD, we compared the virulence of clinical MAC strains isolated from patients with MAC‐PD with a different type of clinical progression by intratracheal injection in female C57BL/6 mice [18, 19] (Figure 3). The growth of M.i.198 in lungs and spleens of C57BL/6 mice after intratracheal infection was higher than that of other clinical M. avium and M. intracellulare strains [18, 19]. The bacterial burden of M.i.198 after 16 weeks of infection remained high, whereas that of other clinical MAC strains decreased [18, 19]. Inflammation in the lungs was to the same degree as that caused by M. avium subsp. avium ATCC25291, which is known to be hypervirulent in mice (Figure 3a). The bacterial burden of M.i.198 in lungs and spleen of C57BL/6 mice after intratracheal infection was higher than that of other clinical M. intracellulare strains exhibiting intermediate and low virulence phenotypes (Figure 3b). M. intracellulare type strain ATCC13950, which was originally isolated from the abdominal lymph node of the 34‐month‐old female in U.S. [35], was eliminated almost completely at 8 weeks of infection. Of note, M.i.198 induced the strongest neutrophilic infiltration in bronchoalveolar lavage fluid, whereas the other two strains exhibiting increased bacterial burden in lungs and spleens induced limited neutrophilic infiltration compared to M.i.198 (Figure 3c). Furthermore, the highest virulence of M.i.198 was demonstrated by the highest mortality on a survival experiment after intratracheally infecting high dose bacteria (2 × 107 CFUs/mouse) (Figure 3d). Virulence of M. intracellulare M.i.198 for C57BL/6 mice. (a) Histology of lungs infected with M. intracellulare M.i.198 or M. avium susp. avium ATCC25291 by hematoxylin‐eosin staining. Mice were intratracheally infected with 1 × 105 CFUs of bacteria. The data were reproduced from our previous publication [18]. (b) Time‐course of bacterial burden in lungs infected with M. intracellulare M.i.198 or the type strain ATCC13950. Mice were intratracheally infected with 1 × 106 CFUs of bacteria. Blue: lungs, Green: spleen, Red: liver. The data were reproduced from our previous publication [19]. (c) Percentage of neutrophils infiltrated in lungs infected with clinical M. intracellulare strains. *: Significant difference following infection with M.i.198 at 4 weeks of infection and following infection with M019 and M021 at 8 weeks of infection, compared with M.i.27, M001, ATCC13950, M003, and MOTT64. †: Significant difference following infection with M.i.198 at 8 and 16 weeks of infection compared with any other strains. The data were reproduced from our previous publication [19]. (d) Survival rate of mice infected with several clinical M. intracellulare strains. Mice were intratracheally infected with 2 × 107 CFUs of bacteria. The data were reproduced from our previous publication [19]. Because M.i.198 is hypervirulent in both the clinical setting and mouse model, it is suitable for assaying drug efficacies. M.i.198 is resistant to clarithromycin (CAM), possibly due to the long‐term exposure to macrolides during the course of therapy; therefore, CAM cannot be used as a control drug when evaluating drug efficacies in infected animals (Table 1). On the other hand, subcutaneous injection of amikacin (AMK) at 100 mg/kg for 6/weeks effectively reduced the lung bacterial burden from approximately 2 × 107 CFUs to around 3 × 105 CFUs (burden in mice without injection of AMK showed approximately 1 × 108 CFUs/lungs) (Figure 4a). Thus, AMK can be employed as a control drug in drug efficacy experiments. M.i.198 can also be used for bioluminescent imaging because it can be transformed with an E. coli‐mycobacteria shuttle vector expressing luciferase (Figure 4b). M.i.198 is considered applicable for monitoring the pathogenesis of MAC‐PD in in vivo situations, such as biofilm formation in the infected lesions [36]. (a) Effectiveness of amikacin (AMK) against M.i.198. AMK at 100 mg/kg AMK subcutaneously for 6 weeks in M.i.198‐infected mice reduced CFUs in the lungs, liver and spleen. Data of 4 mice treated with AMK and those of 4 untreated control mice are shown. *: Significant difference between AMK‐treated group and untreated group by Mann–Whitney U test. The data were originally generated for this Mini‐Review. (b) Ex vivo imaging of the mouse lungs infected with M.i.198 expressing firefly luciferase. The infected lungs contained approximately 1 × 107 CFUs. The image was taken by the in vivo imaging system NEWTON. The data were originally generated for this Mini‐Review. Genotype of M.i.198 We previously reported the whole genome sequence of M.i.198 in 2012 and complete the genome sequence in 2021 [21, 22]. M.i.198 has a 5.4‐Mb chromosome possessing 5329 genes, 5277 protein‐coding sequences (CDSs), 3 rRNAs and 45 tRNAs without plasmids (GenBank GCA_016755915.1). The chromosome of M.i.198 contains a 51‐kb prophage possessing 55 CDSs. We performed comparative genomic analysis of 55 M. intracellulare including M.i.198, and related strains [22] (Figure 5). After excluding the subspecies such as subsp. yongonense and chimaera, M. intracellulare was found to be classified into two genotypes: M. intracellulare (TMI) and M. paraintracellulare‐M. indicus pranii (MP‐MIP). M.i.198 belongs to the typical M. intracellulare (TMI) genotype. Although both M.i.198 and ATCC13950 belong to the typical M. intracellulare (TMI) subgroup, M.i.198 belongs to the different clade from ATCC13950. There are several clinical strains that belong to the same clade as M.i.198, which might have a hypervirulence phenotype similar to M.i.198. However, further studies are needed to elucidate whether or not the genotypes are the major determinant of bacterial virulence. Phylogenetic trees representing the genetic diversity of the M. intracellulare strains. Both M.i.198 and the type strain ATCC13950 belong to the TMI (typical M. intracellulare) group but different subgroups. The strains squared in red correspond to those shown in Figure 3. The data were reproduced from our previous publication [22]. Utility of M.i.198 for Genetic Studies of NTM There are few reports on genetic manipulation of NTM than that of M. tuberculosis (Mtb) because NTM (except for M. smegmatis mc2155, which was produced as a highly transformable strain for gene manipulation) is quite difficult to manipulate, especially slow‐growing NTM [34]. We revealed that transposon mutagenesis can be performed in about 90% of clinical M. intracellulare strains by using mycobacterial phage phAE180 [20]. We identified the universal essential genes and strain‐specific/accessory essential genes by performing transposon sequencing (TnSeq) of nine M. intracellulare strains, including M.i.198, ATCC13950 and other clinical strains [20]. We next constructed the knockdown strains of M.i.198, ATCC13950 and other five clinical strains using CRISPR‐deactivated Cas9 (dCas9) plasmids pRH2502 and pRH2521 to investigate the effect of gene silencing on the in vitro bacterial growth [20, 37] (Figure 6a). Knockdown of universal essential genes such as malate synthase (glcB) and arabinosyltransferase B (embB), the former of which is the target of the novel antituberculous drug phenyl‐diketo acids and the latter of which is the conventional drug targets of ethambutol respectively, suppressed bacterial growth in M.i.198 and ATCC13950 (Figure 6b). By contrast, knockdown of strain‐specific essential genes, such as phosphoenolpyruvate carboxykinase (pckA) and cysteine desulfurase (csd), both of which were identified as essential in M.i.198 but not in ATCC13950 by TnSeq, suppressed the bacterial growth in M.i.198 but not in ATCC13950 (Figure 6c). Genetic tools for M. intracellulare. (a) CRISPR‐dCas9 system for suppressing gene expression in M. intracellulare using pRH2502 and pRH2521 plasmids. dCas9: deactivated Cas9, tetR: tetracycline repressor, tetO: tetracycline operator. (b) Effects of growth suppression in knockdown strains in the representative universal essential genes. The data were reproduced from our previous publication [20]. (c) Effects of growth suppression in knockdown strains in the representative strain‐dependent/accessory essential genes. The data were reproduced from our previous publication [20]. (d) Construction of M. intracellulare deletion mutants using a thermosensitive dominant‐negative selection system via pPR23LHR plasmids. The picture and description were reproduced from our previous publication [38]. GM, gentamycin; Hyg, hygromycin; KM, kanamycin; KO, knockout; SM, streptomycin; X‐gal, 5‐bromo‐4‐chloro‐3‐indolyl‐β‐d‐galactoside. We also constructed a new thermosensitive plasmid containing the gene of ribosomal protein small subunit 12 (rpsL) (Figure 6d). Because RpsL has a dominant negative effect, streptomycin (SM) can be used as a negative‐selection marker for making knockout strains in M. intracellulare [38]. Deletion of the mycobacterial proteasomal genes in the M. intracellulare type strain ATCC13950 was previously reported [38]. And the creation of knockout strains in M.i.198 is ongoing. Limitations of M.i.198 M.i.198 can be utilized for evaluating the effectiveness of drugs in vivo including novel compounds because it shows progressive pathogenesis including high bacterial load, severe inflammation, and in case of high‐dose inoculation, high mortality. M.i.198 can also be utilized for genetic and functional assay to elucidate pathogenesis of MAC‐PD and mode of action of drugs. However, our model of MAC‐PD using M.i.198 has limitations: i.CAM is a key drug for treatment of MAC‐PD [8]. However, M.i.198 is resistant to CAM (Table 1). Macrolide resistance is acquired by mutations and/or target site modification (i.e. methylation) in 23SrRNA, causing reduced affinity between the macrolide and its binding site on the ribosome [39, 40]. The acquired CAM resistance leads to the cross‐resistance to other macrolides [41]. It may be difficult in the animal model infected with M.i.198 to compare drug efficacies with the standard regimen containing CAM, as well as to evaluate efficacies of future novel macrolides. Alternatively, AMK can be used as a positive control drug for evaluating drug efficacies in M.i.198‐infected mice (Figure 4). In contrast to M.i.198, the conventional M. avium strains still have advantage on the evaluation of in vivo drug efficacies in terms of their CAM‐sensitivity as well as the different etiological species of MAC‐PD from M. intracellulare. Various kinds of modalities including M.i.198 as well as conventional M. avium strains help the researchers choose optimal strains to produce the desired achievements. CAM is a key drug for treatment of MAC‐PD [8]. However, M.i.198 is resistant to CAM (Table 1). Macrolide resistance is acquired by mutations and/or target site modification (i.e. methylation) in 23SrRNA, causing reduced affinity between the macrolide and its binding site on the ribosome [39, 40]. The acquired CAM resistance leads to the cross‐resistance to other macrolides [41]. It may be difficult in the animal model infected with M.i.198 to compare drug efficacies with the standard regimen containing CAM, as well as to evaluate efficacies of future novel macrolides. Alternatively, AMK can be used as a positive control drug for evaluating drug efficacies in M.i.198‐infected mice (Figure 4). In contrast to M.i.198, the conventional M. avium strains still have advantage on the evaluation of in vivo drug efficacies in terms of their CAM‐sensitivity as well as the different etiological species of MAC‐PD from M. intracellulare. Various kinds of modalities including M.i.198 as well as conventional M. avium strains help the researchers choose optimal strains to produce the desired achievements. ii.Similar to other MAC strains, M.i.198 does not form cavities in infected mouse lungs, which makes it difficult to elucidate the mechanism of cavity formation in humans. Cavity formation, especially giant cavities, is known to be a major prognostic factor for MAC‐PD in human patients [42]. The clinical course of cases with cavity formation is similar to that of historical tuberculosis without front‐line anti‐tuberculous drugs. The formation of cavities is considered to depend on the difference of immune system in the host species, i.e. the murine immune system is lymphocyte‐dominant, whereas that in humans is neutrophil‐dominant [43]. Not only humans but also rabbits and non‐human primates are known to form mycobacterial lesions called “granuloma” and cavities as a result of necrosis and tissue destruction caused by granuloma when infected with Mtb [44, 45, 46]. The relationship between hypoxia and mycobacterial lesions is well‐studied in Mtb infection [47]. At Mtb‐infected tissues, Mtb bacilli are engulfed with various kinds of immune cells such as macrophages, lymphocytes and epithelioid cells, which causes central caseous necrosis called “granuloma”. The granuloma lesions become hypoxic [47], and hypoxia triggers a destructive cascade such as induction of the transcriptional factor hypoxia inducible factor‐1α (HIF‐1α), which upregulates collagen‐destroying enzymes (i.e. matrix metalloproteases [MMPs]). MMPs destroy lung tissues, and the damaged tissues result in cavities [48]. Moreover, hypoxia increases the survival of neutrophils in infected tissues, causing them to release excess proteases that further destroy lung structure [49]. In contrast that humans and rabbits, non‐human primates form cavities, mice do not form cavities when infected with Mtb [44, 45, 46]. The difference of ability in cavity formation is considered to depend on the difference of immune system and/or some other host factors. However, the reason why not all animals infected with Mtb form cavities despite the mycobacterial lesions become hypoxic has not been fully elucidated yet. About 40 years ago, Drs. Yuichi Yamamura and Yoshihiro Yamamura performed the research at Toneyama Hospital (Osaka, Japan) from 1950s to 1980s, and proved that both glycolipids plus secretory proteins are necessary to form granulomas in rabbit lungs infected with Mtb [44, 45]. Clarification of the specific factors leading to cavity formation may aid in developing novel therapies for disease progression. Similar to other MAC strains, M.i.198 does not form cavities in infected mouse lungs, which makes it difficult to elucidate the mechanism of cavity formation in humans. Cavity formation, especially giant cavities, is known to be a major prognostic factor for MAC‐PD in human patients [42]. The clinical course of cases with cavity formation is similar to that of historical tuberculosis without front‐line anti‐tuberculous drugs. The formation of cavities is considered to depend on the difference of immune system in the host species, i.e. the murine immune system is lymphocyte‐dominant, whereas that in humans is neutrophil‐dominant [43]. Not only humans but also rabbits and non‐human primates are known to form mycobacterial lesions called “granuloma” and cavities as a result of necrosis and tissue destruction caused by granuloma when infected with Mtb [44, 45, 46]. The relationship between hypoxia and mycobacterial lesions is well‐studied in Mtb infection [47]. At Mtb‐infected tissues, Mtb bacilli are engulfed with various kinds of immune cells such as macrophages, lymphocytes and epithelioid cells, which causes central caseous necrosis called “granuloma”. The granuloma lesions become hypoxic [47], and hypoxia triggers a destructive cascade such as induction of the transcriptional factor hypoxia inducible factor‐1α (HIF‐1α), which upregulates collagen‐destroying enzymes (i.e. matrix metalloproteases [MMPs]). MMPs destroy lung tissues, and the damaged tissues result in cavities [48]. Moreover, hypoxia increases the survival of neutrophils in infected tissues, causing them to release excess proteases that further destroy lung structure [49]. In contrast that humans and rabbits, non‐human primates form cavities, mice do not form cavities when infected with Mtb [44, 45, 46]. The difference of ability in cavity formation is considered to depend on the difference of immune system and/or some other host factors. However, the reason why not all animals infected with Mtb form cavities despite the mycobacterial lesions become hypoxic has not been fully elucidated yet. About 40 years ago, Drs. Yuichi Yamamura and Yoshihiro Yamamura performed the research at Toneyama Hospital (Osaka, Japan) from 1950s to 1980s, and proved that both glycolipids plus secretory proteins are necessary to form granulomas in rabbit lungs infected with Mtb [44, 45]. Clarification of the specific factors leading to cavity formation may aid in developing novel therapies for disease progression. Future Studies of NTM‐PD In addition to the issue of cavity formation in MAC‐PD patients, the detailed mechanisms underlying the pathogenesis of MAC‐PD remain to be elucidated. Using the tools we have developed, we consider the following issues to be solved: 1.It is necessary to investigate the mechanism of varying serotypes during the course of disease in humans. As demonstrated in the patient with M.i.198 infection, the serotype of MAC varies. There are two possibilities: (i) involvement of genetic mutations, and (ii) infection by a mixed population [50, 51]. Serotypes can be altered by changing the sugar chain of glycopeptidolipids (GPL) on the cell wall surface. GPL have an amphiphilic moiety, which may be advantageous for survival and replication in hosts. Furthermore, NTM can naturally produce GPL‐deficient mutants called “rough type” (named from the rough colony morphology). For M. abscessus, an emerging pathogen in NTM‐PD demonstrating natural resistance to antibiotics more severely than M. avium and M. intracellulare, rough colony morphology is correlated with high virulence [52]. However, this is not the case in slow growing NTM, including M. avium and M. intracellulare. Little is known about the molecular mechanism on how NTM changes their serotypes. It is necessary to investigate the mechanism of varying serotypes during the course of disease in humans. As demonstrated in the patient with M.i.198 infection, the serotype of MAC varies. There are two possibilities: (i) involvement of genetic mutations, and (ii) infection by a mixed population [50, 51]. Serotypes can be altered by changing the sugar chain of glycopeptidolipids (GPL) on the cell wall surface. GPL have an amphiphilic moiety, which may be advantageous for survival and replication in hosts. Furthermore, NTM can naturally produce GPL‐deficient mutants called “rough type” (named from the rough colony morphology). For M. abscessus, an emerging pathogen in NTM‐PD demonstrating natural resistance to antibiotics more severely than M. avium and M. intracellulare, rough colony morphology is correlated with high virulence [52]. However, this is not the case in slow growing NTM, including M. avium and M. intracellulare. Little is known about the molecular mechanism on how NTM changes their serotypes. 2.It is necessary to elucidate the relationships between unfixed granuloma (less fibrotic change), neutrophil infiltration and biofilm formation, which may enhance bacterial persistence and intolerance to antibiotics. The emergence of new populations such as genetic mutants and hypertolerable mycobacterial cells, may be related to adaptation to the in vivo environment including human bodies. It is necessary to elucidate the relationships between unfixed granuloma (less fibrotic change), neutrophil infiltration and biofilm formation, which may enhance bacterial persistence and intolerance to antibiotics. The emergence of new populations such as genetic mutants and hypertolerable mycobacterial cells, may be related to adaptation to the in vivo environment including human bodies. 3.As macrophages and epithelial cells are key players for mycobacteria to infect and reside in host cells, the cellular pathogenesis of mycobacterial infection has been discussed in terms of these cell types. Recently, other host cells were reported to be involved in the cellular pathogenesis of mycobacterial diseases. For example, red blood cells were revealed to provide an attachment site for MAC [53]. Moreover, capillary vessels are dilated in lungs infected with MAC [47]. These findings suggest the novel mechanism of MAC persistence and further studies are needed to clarify the mechanism of MAC‐specific pathogenesis. As macrophages and epithelial cells are key players for mycobacteria to infect and reside in host cells, the cellular pathogenesis of mycobacterial infection has been discussed in terms of these cell types. Recently, other host cells were reported to be involved in the cellular pathogenesis of mycobacterial diseases. For example, red blood cells were revealed to provide an attachment site for MAC [53]. Moreover, capillary vessels are dilated in lungs infected with MAC [47]. These findings suggest the novel mechanism of MAC persistence and further studies are needed to clarify the mechanism of MAC‐specific pathogenesis. 4.It is necessary to discover biological markers to identify cases of disease progression in order to provide multidisciplinary therapy to improve the prognosis and quality of life. As described above, some MAC‐PD patients show progressive illness even though they undergo chemotherapy, while others show stable illness without chemotherapy [6, 7]. A recent prospective study of 1‐year guideline‐based chemotherapy revealed the poor prognosis group of MAC‐PD patients, which is characterized by the high proportion of neutrophils in peripheral blood despite conversion of sputum culture to negative [30]. In order to determine which case requires medical intervention, it is necessary to find predictive biomarkers for disease outcome in dual aspects including bacterial virulence and host response. It is necessary to discover biological markers to identify cases of disease progression in order to provide multidisciplinary therapy to improve the prognosis and quality of life. As described above, some MAC‐PD patients show progressive illness even though they undergo chemotherapy, while others show stable illness without chemotherapy [6, 7]. A recent prospective study of 1‐year guideline‐based chemotherapy revealed the poor prognosis group of MAC‐PD patients, which is characterized by the high proportion of neutrophils in peripheral blood despite conversion of sputum culture to negative [30]. In order to determine which case requires medical intervention, it is necessary to find predictive biomarkers for disease outcome in dual aspects including bacterial virulence and host response. Conclusion Despite the resistance to clarithromycin, M.i.198 is a promising strain for assessing NTM‐PD in experimental models, including animal infection, gene manipulation and functional analysis, paving a new avenue to understand the molecular pathogenesis of NTM‐PD. Experimental Procedures The photographs of colonies (Figure 2) were originally taken for this Mini‐Review. The data of mouse infection experiments using clinical MAC‐PD strains and ATCC13950 (Figure 3) were reproduced from our previous publication [18, 19]. The data of CFUs and ex vivo imaging data after infecting mice with luciferase‐expressing M.i.198 (Figure 4) were originally produced for this Mini‐Review. We constructed M.i.198 expressing firefly luciferase under the control of the Hsp60 promoter (M.i.198‐pSOHLK) by using E. coli‐mycobacteria episomal shuttle vector pSO246KMr [54, 55]. We infected 6‐week‐old female BALB/cJ mice with 8 × 106 CFUs of M.i.198‐pSOHLK. To prevent the release of the plasmid, mice were kept on drinking water containing 100 μg/mL kanamycin. After 4 months of infection, mice were sacrificed and ex vivo images were taken 10 min after subcutaneous injection of 5 mg of d‐luciferin (Promega, Wisconsin, USA) by Newton FT500 (M&S Instruments Inc., Osaka, Japan). The phylogenetic trees of M. intracellulare strains (Figure 5) were reproduced from our previous publication [22]. The data of gene silencing and the scheme of gene deletion (Figure 6) were reproduced from our previous publication [20, 38]. Ethics Statement We have obtained the written informed consent from the family members of the deceased patient infected with M.i.198. All experiments on animals were conducted in accordance with the relevant guidelines and regulations, and the study complied with the ARRIVE guidelines. The protocols of the ex vivo imaging experiment were approved by the Institutional Review Board of Niigata University (Approved number: SA00506 for the experiments on live vertebrates). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File Figure S1 Figure S2